Evidence map›Paper›PMID 41314681›Full record

ArticleBioconjugate chemistry2025

Seeing What Sticks: Anchoring Capabilities of Moieties for Use in Cell-Conveyed Therapeutics.

Caylie A McGlade, Lauren Haar, Brianna M Vickerman, David S Lawrence

Abstract read
In one paragraph

Article in Bioconjugate chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Caylie A McGladeDepartment of Chemistry, University of North Carolina, Chapel Hill, North Carolina 27599, United States.
Lauren HaarDivision of Chemical Biology and Medicinal Chemistry, University of North Carolina, Chapel Hill, North Carolina 27599, United States.ORCID 0000-0003-3659-793X
Brianna M VickermanDivision of Chemical Biology and Medicinal Chemistry, University of North Carolina, Chapel Hill, North Carolina 27599, United States.
David S LawrenceDepartment of Chemistry, University of North Carolina, Chapel Hill, North Carolina 27599, United States.ORCID 0000-0002-0901-1617

Funding

Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5M
Treatment of Peanut Allergy with Intradermal Administration of ASP0892 (ARA-LAMP-vax): A Randomized, Double-Blind, Placebo-Controlled, Phase I/II StudyUM2AI130836 · NIAID · JOHNS HOPKINS UNIVERSITY · PI WOOD, ROBERT A · 2017 to 2023
$62.1M
Design and Application of Photoresponsive Modules in Circulating ErythrocytesR01HL153744 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LAWRENCE, DAVID S. · 2021 to 2024
$2.7M
UNC Chemical Biology Interface Training ProgramT32GM135122 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Jeffrey Aube · 2021 to 2026
$1.6M
Assembly, Dosimetry, and Assessment of a Platform Technology for the Delivery of ThrombolyticsR01HL176666 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Lauren L Haar · 2025 to 2026
$1.5M
NCI NIH HHS P30 CA016086NHLBI NIH HHS R01 HL153744NHLBI NIH HHS R01 HL176666NIAID NIH HHS UM2 AI130836NIGMS NIH HHS T32 GM135122
6 · The paper itself

Abstract

Red blood cells (RBCs) have been employed to convey and deliver a variety of therapeutic agents, from small molecules to proteins. The therapeutics are typically installed within the RBC interior via a pore-forming process that results in membrane disruption and a partial loss of hemoglobin. An alternative approach, namely appending therapeutics to the RBC surface, has received significantly less attention. Here we focus on the characterization of an array of membrane anchoring modalities (noncovalent, reversible covalent, and covalent). Surface modification is experimentally simpler and structurally less invasive than its membrane disruptive counterpart. This panel is designed, synthesized and assessed with respect to RBC loading capacity, retention, and rate of transfer to other cell populations. The cell surface anchors are appended to a structural scaffold (cobalamin) that can house and deliver therapeutic agents. Imaging studies for a series of representative derivatives reveal that these species are not internalized by the RBCs, consistent with the absence of an active endocytic pathway in mature RBCs. Furthermore, enzymatic digestion of the glycocalyx failed to impair loading or retention, suggesting that the derivatives are likely anchored to the RBC membrane. The structural motifs identified in this study provide a template for the development of membrane tethered therapeutics that are specifically designed to be transported to diseased sites by RBCs.

Indexed as

Cell- and Tissue-Based TherapyDrug CarriersErythrocyte MembraneEndocytosisGlycocalyxHumansVitamin B 12Drug CarriersVitamin B 12

Identifiers

PMID41314681
PMCPMC12733923

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.